HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime

Vaccine

Volumn 25, Issue 42, 2007, Pages 7410-7421

  Duke, Cindy M P ^a   Maguire, Casey A ^a   Keefer, Michael C ^a   Federoff, Howard J ^a   Bowers, William J ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Adenovirus vector; HIV 1 AIDS vaccine; HSV 1 amplicon vector

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HERPES SIMPLEX VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ADENOVIRUS; AMINO ACID SEQUENCE; AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HERPES SIMPLEX; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE; UPREGULATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA PRIMERS; DNA, VIRAL; FEMALE; GENES, ENV; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; PLASMIDS; T-LYMPHOCYTES;

EID: 34748832388     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.015     Document Type: Article

References (67)

1. Johnson P.R., Schnepp B.C., Connell M.J., Rohne D., Robinson S., Krivulka G.R., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79 2 (2005) 955-965
2. Xin K.Q., Urabe M., Yang J., Nomiyama K., Mizukami H., Hamajima K., et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 12 9 (2001) 1047-1061
3. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
4. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
5. Reyes-Sandoval A., Fitzgerald J.C., Grant R., Roy S., Xiang Z.Q., Li Y., et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78 14 (2004) 7392-7399
6. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
7. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79 15 (2005) 9694-9701
8. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20 9 (2004) 989-1004
9. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
10. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., and Liljestrom P. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 13 17 (1997) 1487-1495
11. Caley I.J., Betts M.R., Davis N.L., Swanstrom R., Frelinger J.A., and Johnston R.E. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17 23-24 (1999) 3124-3135
12. Caley I.J., Betts M.R., Irlbeck D.M., Davis N.L., Swanstrom R., Frelinger J.A., et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71 4 (1997) 3031-3038
13. Santra S., Barouch D.H., Korioth-Schmitz B., Lord C.I., Krivulka G.R., Yu F., et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 101 30 (2004) 11088-11093
14. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., and Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72 12 (1998) 10180-10188
15. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5 5 (1999) 526-534
16. Santos K., Duke C.M., and Dewhurst S. Amplicons as vaccine vectors. Curr Gene Ther 6 3 (2006) 383-392
17. Kaur A., Sanford H.B., Garry D., Lang S., Klumpp S.A., Watanabe D., et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357 2 (2007) 199-214
18. Murphy C.G., Lucas W.T., Means R.E., Czajak S., Hale C.L., Lifson J.D., et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74 17 (2000) 7745-7754
19. Hocknell P.K., Wiley R.D., Wang X., Evans T.G., Bowers W.J., Hanke T., et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 76 11 (2002) 5565-5580
20. Santos K., Duke C.M., Rodriguez-Colon S.M., Dakwar A., Fan S., Keefer M.C., et al. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine 25 9 (2007) 1634-1646
21. Willis R.A., Bowers W.J., Turner M.J., Fisher T.L., Abdul-Alim C.S., Howard D.F., et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 12 15 (2001) 1867-1879
22. Santos K., Simon D.A., Conway E., Bowers W.J., Mitra S., Foster T.H., et al. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther 18 2 (2007) 1-13
23. Wade-Martins R., Saeki Y., and Chiocca E.A. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 7 5 Pt 1 (2003) 604-612
24. Wade-Martins R., Smith E.R., Tyminski E., Chiocca E.A., and Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 19 11 (2001) 1067-1070
25. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174 11 (2005) 7179-7185
26. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 2 (2005) 149-156
27. Bucy R.P., Panoskaltsis-Mortari A., Huang G.Q., Li J., Karr L., Ross M., et al. Heterogeneity of single cell cytokine gene expression in clonal T cell populations. J Exp Med 180 4 (1994) 1251-1262
28. Openshaw P., Murphy E.E., Hosken N.A., Maino V., Davis K., Murphy K., et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 182 5 (1995) 1357-1367
29. Roman E., Miller E., Harmsen A., Wiley J., Von Andrian U.H., Huston G., et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 196 7 (2002) 957-968
30. Wu C.Y., Kirman J.R., Rotte M.J., Davey D.F., Perfetto S.P., Rhee E.G., et al. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3 9 (2002) 852-858
31. Hayashi N., Liu D., Min B., Ben-Sasson S.Z., and Paul W.E. Antigen challenge leads to in vivo activation and elimination of highly polarized TH1 memory T cells. Proc Natl Acad Sci USA 99 9 (2002) 6187-6191
32. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 198 12 (2003) 1909-1922
33. Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., and Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 211 (2006) 236-254
34. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional T(H)1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 7 (2007) 843-850
35. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., and Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81 16 (2007) 8468-8476
36. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 12 (2006) 4781-4789
37. Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghten R., Cornette J.L., et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85 9 (1988) 3105-3109
38. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., and Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 2 (1998) 1497-1503
39. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79 14 (2005) 8828-8834
40. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 5 (1998) 2509-2514
41. Maguire C.A., Sapinoro R., Girgis N., Rodriguez-Colon S.M., Ramirez S.H., Williams J., et al. Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. Vaccine 24 5 (2006) 671-682
42. Publicover J., Ramsburg E., and Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 79 21 (2005) 13231-13238
43. Harari A., Vallelian F., and Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 34 12 (2004) 3525-3533
44. Harari A., Petitpierre S., Vallelian F., and Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103 3 (2004) 966-972
45. Harari A., Vallelian F., Meylan P.R., and Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174 2 (2005) 1037-1045
46. Pantaleo G., and Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 6 5 (2006) 417-423
47. Boaz M.J., Waters A., Murad S., Easterbrook P.J., and Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 169 11 (2002) 6376-6385
48. Makedonas G., and Betts M.R. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 28 3 (2006) 209-219
49. Mattapallil J.J., Douek D.C., Buckler-White A., Montefiori D., Letvin N.L., Nabel G.J., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203 6 (2006) 1533-1541
50. Ondondo B.O., Yang H., Dong T., di Gleria K., Suttill A., Conlon C., et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36 10 (2006) 2585-2594
51. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 12 (2006) 1650-1660
52. De Rosa S.C., Lu F.X., Yu J., Perfetto S.P., Falloon J., Moser S., et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 173 9 (2004) 5372-5380
53. Sun Y., Schmitz J.E., Buzby A.P., Barker B.R., Rao S.S., Xu L., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 80 22 (2006) 10950-10956
54. Sad S., and Mosmann T.R. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 153 8 (1994) 3514-3522
55. Wang X., and Mosmann T. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med 194 8 (2001) 1069-1080
56. Yang L., and Mosmann T. Synthesis of several chemokines but few cytokines by primed uncommitted precursor CD4 T cells suggests that these cells recruit other immune cells without exerting direct effector functions. Eur J Immunol 34 6 (2004) 1617-1626
57. Johnston M.I., and Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 356 20 (2007) 2073-2081
58. Wang X., Wiley R.D., Evans T.G., Bowers W.J., Federoff H.J., and Dewhurst S. Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21 19-20 (2003) 2288-2297
59. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007)
60. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172 10 (2004) 6290-6297
61. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 1 (2003) 799-803
62. Wu L., Kong W.P., and Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79 13 (2005) 8024-8031
63. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 10 (2005) 6516-6522
64. Zhu J., Huang X., and Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81 7 (2007) 3170-3180
65. Liu Q., and Muruve D.A. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 10 11 (2003) 935-940
66. Tibbles L.A., Spurrell J.C., Bowen G.P., Liu Q., Lam M., Zaiss A.K., et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 76 4 (2002) 1559-1568
67. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Shih-Wen L., et al. The effect of pre-existing immunity to antigens of adenovirus of the human serotype 5 on immune responses of nonhuman primates to vaccine regimens based on human or chimpanzee-derived adenovirus vectors. J Virol (2007) [Epub ahead of print]